ECE2020 Audio ePoster Presentations Pituitary and Neuroendocrinology (217 abstracts)
Role of 68ga-dotatoc pet/ct in the management of neuroendocrine tumors
Laura Hernández-Montoliu 1 , Inmaculada Peiró 2 , Jose Luis Vercher 3 , Judith Suils 3 , Alexandre Teulé 4 , Cristina Sánchez 4 , N Vilarrasa 1 , Jordi Puig de la Bellacasa 1 , Fernando Guerrero 1 & Carles Villabona 1
1Bellvitge University Hospital, Endocrinology, L’Hospitalet de Llobregat, Spain; 2Institut Català d’Oncologia – L’Hospitalet de Llobregat, Clinical Nutrition Unit, L’Hospitalet de Llobregat, Spain; 3Bellvitge University Hospital, Nuclear Medicine-PET, L’Hospitalet de Llobregat, Spain; 4Institut Català d’Oncologia – L’Hospitalet de Llobregat, Medical Oncology, L’Hospitalet de Llobregat, Spain
Introduction: Primary tumours in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Aims: Evaluate the role of 68Ga-PET in diagnosis, staging, re-evaluation and change of treatment in a group of NET patients with controversial diagnosis.
Material and Methods: In the last 8 months we performed a 68Ga-PET in 19 controversial NET. We collected demographic data, tumor grade, location, NET therapy, 6 months-previous CT and/or MRI and SSTR scintigraphy as well as indication and results of 68Ga-PET.
Results: 19 patients were evaluated, Ten males and nine females, mean age of 56 ± 14.2 years. Location of NET: 5 unknown primary tumor (3 metastatic disease and 2 ectopic ACTH secretion), 7 pancreatic NET (6 out of them with metastatic disease), 4 midgut NET, 2 paragangliomas and 1 gastric NET. Grade of NET: G1: 3; G2: 8; G3 1; NEC: 1. Function: 2 producing ACTH (all with unknown primary tumor). Metastasic disease: 5 with hepatic metastasis, 6 with hepatic and extrahepatic disease and 1 with bone and lung dissemination. Indication of 68Ga-PET: 5 for unknown primary NET, 6 for re-staging, 3 for staging after diagnosis, 4 for evaluatingresponse to treatment and 1 for diagnosis. In 2 patients with metastatic unknown NET, 68Ga-PET found primary midgut NET, but none of unknown ectopic ACTH secretion tumors were found. In 11 patients (57.9%), more lesions in 68Ga-PET than in SSTR scintigraphy were detected. In 9 patients (47.4%) 68Ga-PET allowed changes in decision-making process.
Conclusions: 68Ga-PET can be useful for diagnosis, re-staging and re-evaluation for recurrence and can lead to changes in management in controversial NET patients.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more